Stockscreener 앱 받기
54.85
0.35%
-0.15
시간 외 거래:
54.02
-0.83
-1.51%
Corcept Therapeutics Inc 주식(CORT)의 최신 뉴스
Corcept therapeutics director sells $117,920 in stock - Investing.com
Corcept trial to evaluate Cushing’s and hypertension - Cushing's Disease News
Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation - Markets Insider
Before You Invest, Make Sure You Check This Corcept Therapeutics Inc (NASDAQ: CORT) Analysis - Stocks Register
Corcept Therapeutics Stock Surges Amid Clinical Trial News - TipRanks
Corcept Therapeutics launches study on link between high cortisol and resistant hypertension - Marketscreener.com
Corcept Therapeutics initiates Momentum trial to treat resistant hypertension - TipRanks
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension - StockTitan
Bank of New York Mellon Corp Has $29.72 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept's NDA for its hypercortisolism treatment gets FDA nod - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Corcept Shares Rise More Than 55% in 6 Months: Here's Why - Nasdaq
Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock? - Nasdaq
Corcept Therapeutics Incorporated (CORT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
CORT's Q4 Earnings and Revenues Fall Short of Estimates - MSN
Corcept Therapeutics president sells over $1.1 million in stock By Investing.com - Investing.com South Africa
FDA decision on relacorilant for Cushing’s expected by year’s end - Cushing's Disease News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Connect - Markets Insider
Corcept Therapeutics' (NASDAQ:CORT) Earnings Offer More Than Meets The Eye - Yahoo Finance
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks - The Globe and Mail
Corcept Therapeutics president sells over $1.1 million in stock - Investing.com
Corcept Therapeutics CEO Joseph Belanoff sells $178,097 in stock By Investing.com - Investing.com South Africa
Corcept Therapeutics executive sells $1.18 million in stock - Investing.com
Corcept Therapeutics CEO Joseph Belanoff sells $178,097 in stock - Investing.com India
Corcept Therapeutics executive sells $1.18 million in stock By Investing.com - Investing.com UK
Corcept: Turning A Corner, But Risks Remain (NASDAQ:CORT) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Stockholders to Inquire about Securities Investigation - Markets Insider
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025 - MSN
Corcept Therapeutics: Strong Buy Rating Driven by NDA Acceptance and Promising Trial Outcomes - TipRanks
Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Corcept therapeutics officer sells $277,901 in stock - Investing.com
Corcept Therapeutics Says New Drug Application for Cushing's Syndrome Treatment Filed by FDA - Marketscreener.com
FDA sets December 30, 2025 PDUFA date for Corcept drug - Investing.com
FDA files Corcept’s NDA for Relacorilant as treatment in Hypercortisolism - TipRanks
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation - Markets Insider
HC Wainwright Issues Pessimistic Estimate for CORT Earnings - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
HC Wainwright Issues Positive Outlook for CORT Earnings - Defense World
Corcept Therapeutics (NASDAQ:CORT) Rating Lowered to Hold at StockNews.com - Defense World
Illumine Investment Management LLC Invests $1.03 Million in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Wakefield Asset Management LLLP Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
QRG Capital Management Inc. Purchases 6,163 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Versor Investments LP Sells 12,600 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Piper Sandler Raises Corcept Therapeutics (NASDAQ:CORT) Price Target to $78.00 - Defense World
FourThought Financial Partners LLC Purchases New Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT) - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Investors to Inquire about Securities Investigation - Markets Insider
Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term - Yahoo Finance
Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Given New $78.00 Price Target at Piper Sandler - MarketBeat
HC Wainwright Reaffirms Buy Rating for Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 48% Above Its Share Price - Yahoo Finance
Principal Securities Inc. Purchases 483 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Decoding Corcept Therapeutics Inc (CORT): A Strategic SWOT Insig - GuruFocus.com
Ieq Capital LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Posts Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Corcept Therapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
CORT Stock Declines After Weak Q4 Results - GuruFocus.com
Why Corcept (CORT) Shares Are Sliding Today By Stock Story - Investing.com Canada
Corcept Therapeutics's Options: A Look at What the Big Money is Thinking - Benzinga
Why Corcept (CORT) Shares Are Sliding Today - Financial Content
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Reach Out - Markets Insider
0.49%
1.10%
자본화:
|
볼륨(24시간):